06/29/2026
PEDIG is excited to announce that MTS2 is launched!!!
Click on the NIH announcement to learn more!
To compare the effectiveness of ATROPINE 0.05% eye drops (manufactured by Imprimis Rx, a subsidiary of Harrow.) versus PLACEBO, and of H.A.L.T. MAX (provided by EssilorLuxottica) versus PLACEBO, and of COMBINED versus PLACEBO for slowing myopia progression in axial length (AL) over a two-year treatment period in children aged 5 to less than 12 years with SER myopia of 0.75D to 6.00D and at least 0.75D myopia in both principal meridians of each eye at the time of enrollment.
“Supporting rigorous clinical research reflects our commitment to scientific excellence and evidence generation,” said Olga Prenat, MSc Optom, FEAOO, EMBA, Global Head of Medical Affairs, EssilorLuxottica. Carl Spear, OD, MBA, FAAO, Chief Medical Officer NA EssilorLuxottica agreed, adding, “Is It is an honor for EssilorLuxottica to support the PEDIG study funded by the NIH. MTS2 has the potential to shape the future of pediatric myopia management.”
"Harrow is proud to support the NIH and PEDIG in advancing research that may help improve outcomes for children affected by progressive myopia,” said Mark L. Baum, Chief Executive Officer of Harrow.
PEDIG is excited to announce that MTS2 is launched!!! Click on the NIH announcement to learn more! To compare the effectiveness of ATROPINE 0.05% eye drops (manufactured by Imprimis Rx, a subsidiary of Harrow.) versus PLACEBO, and of H.A.L.T. MAX (provided by EssilorLuxottica) versus PLACEBO, and of...
